Molecular-Biological Methods of Quality Control of Biological Active Substances Produced by Recombinant DNA Technology

Biotechnological products manufactured by recombinant DNA technology are widely used nowadays. According to the national and  international requirements the amount of residual host cell DNA in  such products should not exceed 10 ng per dose. However, for  products intended for frequent or long-term use, this amount must  not exceed 100 pg per dose. This article describes methods most  frequently used for quantification of residual host cell DNA in  biological active substances contained in biotechnological products:  molecular hybridization with biotin- or digoxigenin-labelled DNA- probes (semiquantitative method), Threshold system, real-time PCR, method based on the use of a fluorescent reagent (assays). If  a method based on the use of a fluorescent reagent or real-time PCR are used to replace the current procedure, it is necessary to  demonstrate their validity, e.g. by comparing the results of residual DNA quantification obtained by the two methods — the new one and the current one. The article dwells upon the advantages and  disadvantages of the methods and potential sources of uncertainty.  It highlights the importance of using appropriately certified reference standards and retention samples. The biological active substances  included into the State Register of Medicinal Products conform to the international requirements in terms of the amount of residual host cell DNA.

1. Общая фармакопейная статья 1.7.1.0007.15 Лекарственные средства, получаемые методами рекомбинантных ДНК. Государственная фармакопея Российской Федерации. ХIII изд. Т. 2, М.; 2015. [General Monograph 1.7.1.0007.15 Drugs Produced by Recombinant DNA Methods. The State Pharmacopoeia of the Russian Federation. 13th ed. V. 2. Мoscow; 2015 (In Russ.)]

2. Руководство по проведению доклинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Ч. 2. М.: Гриф и К; 2013. [Guidance on Preclinical Evaluation of Medicines (Immunobiological Drugs). Part 2. Мoscow: Grif and K; 2013 (In Russ.)]

3. Нормативные правовые акты в сфере обращения лекарственных средств в рамках Евразийского экономического союза. Разработка и проведение исследований биологических лекарственных средств. Т. 3. М.: Ремедиум; 2017. [Normative Legal Acts in the Sphere of Medicinal Products Circulation within the Framework of the Eurasian Economic Union. Development and Carrying out of Research of Biological Medicinal Products. V. 3. Moscow: Remedium; 2017 (In Russ.)]

4. Andersen DC, Krummen L. Recombinant Protein Expression for Therapeutic Applications. Curr Opin Biotechnol. 2002;13(2):117–23.

5. Chu L, Robinson DK. Industrial Choices for Protein Production by Large-Scale Cell Culture. Curr Opin Biotechnol. 2001;12(2):180–7.

6. Sheng L, Cai F, Zhu Y, Pal A, Athanasiou M, Orrison B, et al. Oncogenicity of DNA in vivo: Tumor Induction with Expression Plasmids for Activated H-ras and C-myc. Biologicals. 2008;36(3):184–97. DOI: 10.1016/j.biologicals.2007.11.003

7. Wang X, Morgan DM, Wang G, Mozier NM. Residual DNA Analysis in Biologics Development: Review of Measurement and Quantitation Technologies and Future Directions. Biotechnol Bioeng. 2012;109(2):307–17. DOI: 10.1002/bit.23343

8. Peden K, Sheng L, Pal A, Lewis A. Biological Activity of Residual Cell-Substrate DNA. Dev Biol (Basel) 2006;123:45–53.

9. Wolter T, Richter A. Assays for Controlling Host-Cell Impurities in Biopharmaceuticals. BioProcess Int. 2005;3(2):40–6.

10. Requirements for the Use of Animal Cells as in vitro Substrates for the Production of Biologicals. In: WHO Expert Committee on Biological Standardization. Forty-seventh report. WHO; 1998 (WHO Technical Report Series, No. 878), Annex 1.

11. Meeting Report. WHO Study Group on Cell Substrates for Production of Biologicals; 2007. Available from: http://www.who.int/biologicals/publications/meetings/areas/vaccines/cells/Cells.FINAL.MtgRep.IK.26_Sep_07.pdf

12. WHO. Guidelines on the Quality, Safety, and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA Technology. Replacement of Annex 3 of WHO Technical Report Series, No. 814. 2013. Available from: http://www.who.int/biologicals/biotherapeutics/rDNA_DB_final_19_Nov_2013.pdf

13. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 1997. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/.../UCM153182.pdf

14. Ikeda Y, Iwakiri S, Yoshimori T. Development and Characterization of a Novel Host Cell DNA Assay Using Ultra- Sensitive Fluorescent Nucleic Acid Stain «PicoGreen». J Pharm Biomed Anal. 2009;49(4):997–1002. DOI: 10.1016/j.jpba.2009.01.022

15. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen Reagent and Development of a Fluorescence-Based Solution Assay for Double-Stranded DNA Quantitation. Anal Biochem. 1997;249(2):228–38. DOI: 10.1006/abio.1997.2177

16. Dragan АI, Casas-Finet JR, Bishop ES, Strouse RJ, Schenerman MA, Geddes CD. Characterization of PicoGreen Interaction with dsDNA and the Origin of Its Fluorescence Enhancement upon Binding. Biophys J. 2010;99(9):3010–9. DOI: 10.1016/j.bpj.2010.09.012

17. МУК 4.1/4.2.588-96. Методы контроля медицинских иммунобиологических препаратов, вводимых людям. Минздрав России, М.; 1998. [Methodical Instructions MUK 4.1 / 4.2.588-96 «Methods of Control Medical Immunobiological Drugs Administered to People». Ministry of Health of Russia, Moscow; 1998 (In Russ.)]

18. Gebeyehu G, Rao PY, SooChan P, Simms DA, Klevan L. Novel Biotinylated Nucleotide — Analogs for Labeling and Colorimetric Detection of DNA. Nucleic Acids Res. 1987;15(11):4513–34.

19. DIG Application Manual for Filter Hybridization. Roche Diagnostics GmbH; 2008. Available from: https://www.sigmaaldrich. com/content/dam/sigma-aldrich/docs/Roche/General_Information/1/dig-application-manual-for-filter-hybridisation-iris.pdf

20. Gijsbers L, Koel B, Weggeman M, Goudsmit J, Havenga M, Marzio G. Quantification of Residual Host Cell DNA in Adenoviral Vectors Produced on PER. C6 Cells. Hum Gene Ther. 2005;16(3):393–8. DOI: 10.1089/hum.2005.16.393

21. Gregory CA, Rigg GP, Illidge CM, Matthews RC. Quantification of Escherichia coli Genomic DNA Contamination in Recombinant Protein Preparations by Polymerase Chain Reaction and Affinity-Based Collection. Anal Biochem. 2001;296(1):114–21. DOI: 10.1006/abio.2001.5237

22. Wang KY, Guo YJ, Sun SH, Shi K, Zhang S, Wang KH, et al. 16S rRNA Gene Probe Quantitates Residual Host Cell DNA in Pharmaceutical-Grade Plasmid DNA. Vaccine. 2006;24(14):2656–61. DOI: 10.1016/j.vaccine.2005.11.066

23. Ребриков ДВ, Саматов ГА, Трофимов ДЮ, Семенов ПА, Савилова АМ, Кофиади ИА, Абрамов ДД. ПЦР «в реальном времени». М.: Бином. Лаборатория знаний; 2009. [Rebrikov DV, Samatov GA, Trofimov DYu, Semenov PA, Savilova AM, Kofiadi IA, Abramov DD. PCR «Real Time». Moscow: Binom. Laboratoriya znaniy; 2009 (In Russ.)]

24. Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR. Basic Principles of Real-Time Quantitative PCR. Expert Rev Mol Diagn. 2005;5(2):209–19.

25. Кузнецов ВВ, Кузнецова ВВ, Романова ГА, ред. Молекулярно-генетические и биохимические методы в современной биологии растений. М.: Бином. Лаборатория знаний; 2012. [Kuznetsov VV, Kuznetsova VV, Romanova GA, eds. Molecular-Genetic and Biochemical Methods in Modern Plant Biology. Moscow: Binom. Laboratoriya znaniy; 2012 (In Russ.)]

26. Wilchek M, Bayer EA. The Avidin-Biotin Complex in Bioanalytical Application. Anal Biochem. 1988;171(1):1–32.

27. Blakeley RL, Zerner B. Jack Bean Urease: the First Nickel Enzym. J Mol Catalysis. 1984;23(2–3);263–92.

28. Ishikawa E, Imagawa M, Hashida S, Yoshitake S, Hamaguchi Y, Ueno T. Enzyme- Labeling of Antibodies and Their Fragments for Enzyme Immunoassay and Immunohistochemical Staining. J Iimmunoassay. 1983;4(3):209–327.

29. Molecular Devices. The Threshold DNA Assay Kit. Available from: https://www.moleculardevices.com/reagents-supplies/assay-kits/contaminant-detection-assays

30. Mehta S, Keer JT. Performance Characteristics of Host-Cell DNA Quantification Methods. BioProcess Int. 2007;4(9):44–58.

31. EURACHEM/CITAC Guide. Quantifying Uncertainty in Analytical Measurement. 2nd ed.; 2000. Available from: https://eurachem.org/images/stories/Guides/pdf/QUAM2000- 1.pdf

32. Волкова РА, Фадейкина ОВ. Проблемы оценки неопределенности методик испытаний и стандартных образцов иммунобиологических лекарственных средств. БИОпрепараты. Профилактика, диагностика, лечение 2017;17(1):27–31. [Volkova RA, Fadeikina OV. The Problem of Estimating the Uncertainty of Test Methods and Standard Samples of Immunobiological Medicines BIOpreparations. Prevention, Diagnosis, Treatment 2017;17(1):27–31 (In Russ.)] DOI: 10.30895/2221-996X-2017-17-1-27-31

33. Cygnus Technologies. CHO DNA Amplification Kit in Tubes. Available from: https://cygnustechnologies.com/product_info.php/products_id/442/cpID/53

34. Волкова РА, Фадейкина ОВ, Климов ВИ, Саканян ЕИ, Олефир ЮВ, Меркулов ВА и др. Актуальные вопросы стандартных образцов в сфере обращения биологических лекарственных средств. БИОпрепараты. Профилактика, диагностика, лечение 2016;16(4):229–36. [Volkova RA, Fadeikina OV, Klimov VI, Sakanyan EI, Olefir YuV, Merkulov VA, et al. Topical Issues Related to Reference Standards in the Sphere of Circulation of Biological Products. BIOpreparations. Prevention, Diagnosis, Treatment 2016;16(4):229–36 (In Russ.)] DOI: 10.30895/2221-996X-2016-16-4-229-236

35. Бондарев ВП, Борисевич ИВ, Волкова РА, Фадейкина ОВ. Проблемы аттестации отраслевых стандартных образцов для контроля качества иммунобиологических лекарственных препаратов. Ведомости Научного центра экспертизы средств медицинского применения 2013;(2):28–32. [Bondarev VP, Borisevich IV, Volkova RA, Fadeykina OV. Industry Reference Standards Certification for the Control of Medical Immunobiological Preparations. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2013;(2):28–32 (In Russ.)]

36. Общая фармакопейная статья 1.1.0012.15 Валидация аналитических методик. Государственная фармакопея Российской Федерации, ХIII изд. Т. 1, М.; 2015. [General Monograph 1.1.0012.15 Validation of Analytical Techniques. The State Pharmacopoeia of Russian Federation. 13th ed. V. 1. Мoscow; 2015 (In Russ.)]